AdipoGen Life Sciences

Elbasvir

As low as CHF 50.00

In stock

AG-CR1-3729-M0011 mgCHF 50.00

AG-CR1-3729-M0055 mgCHF 145.00

AG-CR1-3729-M02525 mgCHF 435.00

More Information
Product Details
Synonyms	MK-8742
Product Type	Chemical
Properties
Formula	C₄₉H₅₅N₉O₇
MW	882.0
CAS	1370468-36-2
Purity Chemicals	≥98% (HPLC)
Appearance	White to off-white solid.
Solubility	Soluble in DMSO (20mg/ml), DMF (25mg/ml) or ethanol (25mg/ml).
Identity	Determined by ¹H-NMR.
InChi Key	BVAZQCUMNICBAQ-ISSDNXAZSA-N
Smiles	O=C(N1CCCC1C2=NC=C(C3=CC4=C(N(C5=C4)[C@@H](OC6=C5C=CC(C7=CN=C(N7)[C@@H]8CCCN8C([C@H](C(C)C)NC(OC)=O)=O)=C6)C9=CC=CC=C9)C=C3)N2)[C@@H](NC(OC)=O)C(C)C
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Keep cool and dry.
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Description

Elbasvir is a direct-acting antiviral drug that potently inhibits hepatitis C virus (HCV) non-structural protein 5A (NS5A). NS5A is essential for HCV RNA synthesis and viral assembly, and elbasvir inhibits the assembly of new viral replicase complexes when used at a concentration of 50 pM.
It exhibits potent inhibitory activity against a broad range of HCV genotypes.
Formulations containing elbasvir have been used alone and in combination with NS3/4A protease inhibitors in the treatment of HCV.
Identified as a potential inhibitor of SARS-CoV-2, responsible for COVID-19.

Product References

Discovery of MK-8742: An HCV NS5A Inhibitor With Broad Genotype Activity: C.A. Coburn, et al.; ChemMedChem 8, 1930 (2013)
Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors: D.R. McGivern, et al.; Gastroenterology 147, 453 (2014) (Review)
Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir: R. Liu, et al.; Antimicrob. Agents Chemother. 59, 6922 (2015)
The combination of grazoprevir, a Hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons: F.C. Lahser, et al.; Antimicrob. Agents Chemother. 60, 2954 (2016)
Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C: A.M. Bell, et al.; Int. J. Hepatol. 2016, 3852126 (2016) (Review)
Antiviral activity and resistance analysis of NS3/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir in Hepatitis C virus GT4 replicons: E. Asante-Appiah, et al.; Antimicrob. Agents Chemother. 61, e00363 (2017)
Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study: J. Wang; Preprints (2020)
Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins: M. Balasubramaniam & R.J. Shmookler Reis; ChemRxiv (Preprint) (2020)

Call	+41 61 926 6040
Fax	+41 61 926 6049